Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Dietary Intervention and Exercise Training (DIET) in Moderate to Severe Chronic Kidney Disease

1. november 2010 opdateret af: Vanderbilt University

The oxidative stress and inflammatory state is known to contribute to the pathogenesis of atherosclerosis, and is predictive of cardiovascular events and mortality rates in the general population and patients with chronic kidney disease (CKD), particularly in patients with end stage renal disease (ESRD) on dialysis therapy 1. Increased oxidative stress and inflammation has been identified in all stages of CKD, ranging from moderate renal insufficiency to ESRD. However, the pathophysiology of increased oxidative stress and inflammation associated with the development of CKD is currently poorly understood.

There is also concern about the epidemic of obesity in the United States, as the overall health status of the general population is adversely affected by increasing adiposity. Recent studies indicate a strong relationship between adiposity and incident CKD. Furthermore, the presence of an elevated body mass index (BMI) is an independent predictor for progression to ESRD, even after additional adjustments for baseline blood pressure and the presence or absence of diabetes mellitus. Limited data in the general population show that healthy lifestyle interventions, such as exercise and dietary caloric restriction, either alone or in combination, reduce the inflammatory and oxidative stress burden seen in obese subjects. The impact of healthy lifestyle modifications on inflammation and oxidative stress has not been investigated in the obese CKD population. Based on the foregoing observations, the purpose of this investigation will be to determine whether healthy lifestyle interventions in the form of low-impact aerobic exercise and dietary calorie restriction in obese subjects (BMI ≥ 30kg/m2) with moderate to severe (Stage III-IV) CKD [estimated glomerular filtration rate (GFR) 20-59 ml/min] will improve oxidative stress, inflammation, insulin resistance, adipocytokines, endothelial dysfunction, and quality of life.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

3

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37232
        • Vanderbilt University Medical Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Patients with Stage III-IV (estimated GFR 20-59 min/ml) chronic kidney disease measured by MDRD formula.
  2. BMI ≥ 30 kg/m2
  3. Age > 18 or < 65 years.
  4. Life expectancy greater than one year.
  5. Ability to understand and provide informed consent for participation in the study.

Exclusion Criteria:

  1. Active inflammatory disease such as: AIDS (HIV seropositivity is not an exclusion criteria), active hepatitis C or B, active gout, other active inflammatory diseases.
  2. Active malignancy excluding basal or squamous cell carcinoma of the skin.
  3. Patients suffering from Type I Diabetes Mellitus
  4. Patients with reduced daily caloric intake at baseline (≤ 2000 kcal/day) or malnutrition.
  5. Patients who are already on a consistent and rigorous exercise regimen.
  6. Gastrointestinal dysfunction requiring parental nutrition.
  7. History of functional kidney transplant < 6 months prior to study entry.
  8. Anticipated live donor kidney transplant over study duration.
  9. Patients taking anti-inflammatory medication except aspirin < 325mg/day over the past 30 days.
  10. Patients taking Vitamin E supplements > 60 IU/day, vitamin C > 500mg/day over the past 30days.
  11. Patients taking any prednisone therapy.
  12. Hospital admission within the last 30 days.
  13. On experimental drug protocols.
  14. Significant cardiac or vascular disease (symptomatic disease; CV event(s) within the last year; significant occlusive atherosclerotic disease or ischemic disease on non-invasive or invasive diagnostic procedures).
  15. Significant physical disability or immobility (joint disease, joint replacement, muscular disorders).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: 1
low-impact aerobic exercise group
subjects will undergo supervised physical activity for a maximum of 30-60 minutes, every other day, 3 days per week for 3 months; to offer variety in the exercise prescription, subjects will alternately use a treadmill, an elliptical trainer, a Nu-Step cross-trainer and a recumbent stationary bicycle
Aktiv komparator: 2
dietary restriction group
subjects will undergo a 20% reduction in total daily calories from their usual daily energy consumption every day for 3 months
Ingen indgriben: 3
control group

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
a statistically significant decrease in plasma F2-isoprostanes, a specific oxidative stress marker
Tidsramme: 3 months
3 months
a statistically significant decrease in hs-CRP, a specific inflammatory marker
Tidsramme: 3 months
3 months

Sekundære resultatmål

Resultatmål
Tidsramme
significant changes in additional markers of oxidative stress and inflammation
Tidsramme: 3 months
3 months
significant changes in insulin resistance and adipocytokines
Tidsramme: 3 months
3 months
a significant improvement in endothelial function as measured by brachial artery FMD
Tidsramme: 3 months
3 months
a significant improvement in quality of life scores
Tidsramme: 3 months
3 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Alp Ikizler, MD, Vanderbilt University Medical Center

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. december 2007

Primær færdiggørelse (Faktiske)

1. april 2009

Studieafslutning (Faktiske)

1. april 2009

Datoer for studieregistrering

Først indsendt

18. december 2007

Først indsendt, der opfyldte QC-kriterier

19. december 2007

Først opslået (Skøn)

27. december 2007

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

3. november 2010

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. november 2010

Sidst verificeret

1. november 2010

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 070990

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner